CytoMed Therapeutics shares surge 10.14% after-hours on cell therapy advancements and strategic partnerships.

CytoMed Therapeutics surged 10.14% in after-hours trading following a Bloomberg-style news update highlighting its advancements in cell therapies, strategic partnerships, and robust financial management. The company reported a 20.01% intraday gain driven by optimism over its Natural Killer cell therapy pipeline and collaborations with entities like Enterprise Singapore, which bolster expansion plans. Financially, CytoMed’s $10M in assets, a balanced leverage ratio of 1.1, and revenue growth near $853,000 reinforced investor confidence in its sustainable innovation approach. The after-hours rally aligns with broader market reactions to its operational strides and long-term therapeutic potential.